Editorial Endocrinology/Diabetes/Metabolism Trauma
Rethinking in-hospital mortality in patients on haemodialysis: the role of frailty screening

Rethinking in-hospital mortality in patients on haemodialysis: the role of frailty screening

Authors

Leo Mueller

Leo Mueller

Toronto General Hospital, South Georgia

Corresponding
Zainab Tanaka

Zainab Tanaka

American University of Beirut Medical Center, Jordan

Omar Rossi

Omar Rossi

Aga Khan University Hospital, Puerto Rico

Karim Nakamura

Karim Nakamura

Royal Melbourne Hospital, Comoros

Published

June 8, 2025

Paper ID

PAP-000250

Status

Published

DOI

10.65712/tmj.test000508

Rethinking in-hospital mortality in patients on haemodialysis: the role of frailty screening

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: The cost of in-hospital mortality to health systems is substantial. Methods: Missing data were handled with multiple imputation. Results: 1629 participants were included (median age 37 years). Serious adverse events were rare and similar between groups. Conclusion: Residual confounding cannot be excluded.

References

1. Okafor I, Moreau G, et al. SGLT2 inhibitors and health-related quality of life. Diabetes Care. 2018;389(6):5-1576.

2. Herrera U, Nasser E, et al. A sepsis alert system and ventilator-free days. Eur Heart J. 2025;260(5):14-1024.

3. Rahman G, Kim U, et al. Continuous glucose monitoring and 30-day readmission. Ann Intern Med. 2013;86(9):352-1661.

4. Costa U, Ahmed C, et al. Pharmacist-led medication review and surgical site infection. Diabetes Care. 2025;270(10):152-1322.

5. Schmidt M, Lindqvist P, et al. SGLT2 inhibitors and acute kidney injury. Lancet. 2016;300(3):692-983.

6. Moreau J, Yilmaz M, et al. An enhanced recovery pathway and medication adherence. Diabetes Care. 2019;132(5):623-916.

7. Kim N, Kaur A, et al. Delayed cord clamping and medication adherence. Diabetes Care. 2012;366(10):86-1262.

8. Dubois U, Lindqvist S, et al. Delayed cord clamping and falls. Diabetes Care. 2017;215(8):495-1270.

Introduction

Practice around frailty screening varies widely between centres. Guidelines make only a weak recommendation on frailty screening. Earlier studies of frailty screening were small or single-centre.

Earlier studies of frailty screening were small or single-centre. in-hospital mortality remains a leading cause of avoidable harm among patients on haemodialysis.

Materials and Methods

We conducted a prospective cohort study across 4 centres between 2017 and 2021. Analyses were adjusted for age, sex and baseline severity.

Eligible participants were patients on haemodialysis. The primary outcome was in-hospital mortality, assessed blind to allocation.

Eligible participants were patients on haemodialysis. Missing data were handled with multiple imputation. We conducted a prospective cohort study across 6 centres between 2014 and 2023.

Results

Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups.

in-hospital mortality occurred in 14% of the intervention group versus 22% of controls. in-hospital mortality occurred in 4% of the intervention group versus 33% of controls.

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.46 (95% CI 0.47 to 0.71).

GroupnEvents
Age ≥ 6578830
Centre A63844
Age ≥ 6516090
Age ≥ 6562827
Age < 6581934
Control52075
Centre A6666
TABLE 1: Subgroup analysis
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Change in in-hospital mortality
Shown for patients on haemodialysis; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Change in in-hospital mortality
Shown for patients on haemodialysis; error bars are 95% confidence intervals.

in-hospital mortality occurred in 22% of the intervention group versus 29% of controls. The adjusted odds ratio was 0.82 (95% CI 0.36 to 0.87). The adjusted odds ratio was 0.90 (95% CI 0.25 to 0.68). Serious adverse events were rare and similar between groups.

Discussion

Implementation will depend on staffing, cost and local protocols. Future work should test frailty screening in a pragmatic multicentre trial.

Implementation will depend on staffing, cost and local protocols. Future work should test frailty screening in a pragmatic multicentre trial.

Strengths include the sample size and blinded outcome assessment. These findings suggest that frailty screening is associated with better in-hospital mortality in patients on haemodialysis. Implementation will depend on staffing, cost and local protocols.

Strengths include the sample size and blinded outcome assessment. Future work should test frailty screening in a pragmatic multicentre trial. These findings suggest that frailty screening is associated with better in-hospital mortality in patients on haemodialysis.

Conclusions

Frailty screening is a reasonable option for patients on haemodialysis to improve in-hospital mortality.

Appendices

The statistical analysis plan is in the online supplement.